Frontiers in Oncology | Thoracic Oncology

Original Research

Published on 22 Oct 2020

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

in Thoracic Oncology

Mohammed Safi
Ravindran Kanesvaran
Mohammed Alradhi
Abdullah Al-Danakh
Feng Ping
Najeeb Al-Sabai
Xiu Shan
Jiwei Liu

Frontiers in Oncology

doi 10.3389/fonc.2020.572380

6,851 views
6 citations

Review

Published on 20 Oct 2020

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

in Thoracic Oncology

Karam Khaddour
Sandra L. Gomez-Perez
Nikita Jain
Jyoti D. Patel
Yanis Boumber

Frontiers in Oncology

doi 10.3389/fonc.2020.576314

10,187 views
28 citations

Review

Published on 20 Oct 2020

The Resistance Mechanisms of Lung Cancer Immunotherapy

in Thoracic Oncology

Fen Wang
Shubin Wang
Qing Zhou

Frontiers in Oncology

doi 10.3389/fonc.2020.568059

20,699 views
85 citations

Systematic Review

Published on 20 Oct 2020

The Favorable Prognostic Factors for Superior Sulcus Tumor: A Systematic Review and Meta-Analysis

in Thoracic Oncology

Xiaohu Hao
Zihuai Wang
Diou Cheng
Jian Zhou
Nan Chen
Qiang Pu
Lunxu Liu

Frontiers in Oncology

doi 10.3389/fonc.2020.561935

4,841 views
2 citations

Original Research

Published on 19 Oct 2020

Evaluation of the Effect of Lymph Node Status on the Survival of Non-Small Cell Lung Cancer Patients With Brain Metastases: Applications of a Novel Grade Prognostic Assessment Score Model Involving N Stage

in Thoracic Oncology

Jianfei Zhu
Wuping Wang
Shuonan Xu
Chenghui Jia
Qingqing Zhang
Yanmin Xia
Wenchen Wang
Miaomiao Wen
Xuejiao Wang
Hongtao Wang

Frontiers in Oncology

doi 10.3389/fonc.2020.563700

3,205 views
7 citations

Original Research

Published on 15 Oct 2020

Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis

in Thoracic Oncology

Juanni Li
Kuan Hu
Lei Zhou
Jinzhou Huang
Shuangshuang Zeng
Zhijie Xu
Yuanliang Yan

Frontiers in Oncology

doi 10.3389/fonc.2020.560615

5,119 views
9 citations

Original Research

Published on 14 Oct 2020

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients

in Thoracic Oncology

Meiying Guo
Wanlong Li
Butuo Li
Bing Zou
Shijiang Wang
Bingjie Fan
Xindong Sun
Linlin Wang

Frontiers in Oncology

doi 10.3389/fonc.2020.571380

4,112 views
5 citations

Original Research

Published on 14 Oct 2020

Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis

in Thoracic Oncology

Nannan Li
Lili Hou
Shu Li

Frontiers in Oncology

doi 10.3389/fonc.2020.522407

4,623 views
5 citations

Original Research

Published on 14 Oct 2020

Thermal Ablation Versus Wedge Resection for Stage I Non-small Cell Lung Cancer Based on the Eighth Edition of the TNM Classification: A Population Study of the US SEER Database

in Thoracic Oncology

Chenxi Zeng
Jiawei Lu
Yitao Tian
Xiangning Fu

Frontiers in Oncology

doi 10.3389/fonc.2020.571684

5,071 views
24 citations

Original Research

Published on 14 Oct 2020

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey

in Thoracic Oncology

Chiara Catania
Gianluca Spitaleri
Ester Del Signore
Ilaria Attili
Davide Radice
Valeria Stati
Letizia Gianoncelli
Stefania Morganti
Filippo de Marinis

Frontiers in Oncology

doi 10.3389/fonc.2020.584612

6,093 views
23 citations

Review

Published on 09 Oct 2020

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

in Thoracic Oncology

Rilan Bai
Lingyu Li
Xiao Chen
Naifei Chen
Wei Song
Jiuwei Cui

Frontiers in Oncology

doi 10.3389/fonc.2020.575472

18,002 views
56 citations

Original Research

Published on 09 Oct 2020

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

in Thoracic Oncology

Wenxian Wang
Zhangzhou Huang
Zongyang Yu
Wu Zhuang
Weijun Zheng
Zhijian Cai
Lei Shi
Xinmin Yu
Guangyuan Lou
Wei Hong

Frontiers in Oncology

doi 10.3389/fonc.2020.572853

5,378 views
24 citations

Original Research

Published on 30 Sep 2020

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer

in Thoracic Oncology

Xiaoyang Zhai
Xuquan Jing
Ji Li
Yaru Tian
Shuhui Xu
Min Wang
Hui Zhu

Frontiers in Oncology

doi 10.3389/fonc.2020.556275

5,785 views
7 citations

Original Research

Published on 30 Sep 2020

Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma

in Thoracic Oncology

Yang Liu
Wenxiao Jia
Ji Li
Hui Zhu
Jinming Yu

Frontiers in Oncology

doi 10.3389/fonc.2020.587343

5,280 views
18 citations

Perspective

Published on 30 Sep 2020

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1

in Thoracic Oncology

Evgeny N. Imyanitov
Alexandr O. Ivantsov
Ilya V. Tsimafeyeu

Frontiers in Oncology

doi 10.3389/fonc.2020.549198

8,805 views
4 citations

Original Research

Published on 29 Sep 2020

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

in Thoracic Oncology

Feliciano Barrón
Roberto Sánchez
Marisol Arroyo-Hernández
Carolina Blanco
Zyanya L. Zatarain-Barrón
Rodrigo Catalán
Maritza Ramos-Ramírez
Andrés F. Cardona
Diana Flores-Estrada
Oscar Arrieta

Frontiers in Oncology

doi 10.3389/fonc.2020.570233

6,969 views
38 citations

Original Research

Published on 25 Sep 2020

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer

in Thoracic Oncology

Alice Boscolo
Francesco Fortarezza
Francesca Lunardi
Giovanni Comacchio
Loredana Urso
Stefano Frega
Jessica Menis
Laura Bonanno
Valentina Guarneri
Federico Rea

Frontiers in Oncology

doi 10.3389/fonc.2020.564915

4,463 views
11 citations

Review

Published on 25 Sep 2020

SABR-BRIDGE: Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic

in Thoracic Oncology

Biniam Kidane
Jonathan Spicer
Julian O. Kim
Pierre-Olivier Fiset
Bassam Abdulkarim
Richard Malthaner
David Palma

Frontiers in Oncology

doi 10.3389/fonc.2020.580189

10,692 views
20 citations

Perspective

Published on 25 Sep 2020

Telemedicine in Oncology: Delivering on an Overdue Promise in the COVID-19 Era

in Thoracic Oncology

Howard (Jack) West

Frontiers in Oncology

doi 10.3389/fonc.2020.578888

8,724 views
22 citations

Original Research

Published on 24 Sep 2020

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

in Thoracic Oncology

Luochengling Xiang
Xiao Fu
Xiao Wang
Wenyuan Li
Xiaoqiang Zheng
Kejun Nan
Tao Tian

Frontiers in Oncology

doi 10.3389/fonc.2020.559896

5,095 views
17 citations

Mini Review

Published on 24 Sep 2020

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

in Thoracic Oncology

Maitane Ocáriz-Díez
Mara Cruellas
Marta Gascón
Rodrigo Lastra
Luis Martínez-Lostao
Ariel Ramírez-Labrada
José Ramón Paño
Andrea Sesma
Irene Torres
Alfonso Yubero

Frontiers in Oncology

doi 10.3389/fonc.2020.568939

9,714 views
28 citations

Review

Published on 23 Sep 2020

Exosome-Derived LncRNAs in Lung Cancer

in Thoracic Oncology

Tao Fan
Nan Sun
Jie He

Frontiers in Oncology

doi 10.3389/fonc.2020.01728

10,081 views
36 citations

Original Research

Published on 23 Sep 2020

Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma

in Thoracic Oncology

Xiaoguang Qi
Chunyan Qi
Boyu Qin
Xindan Kang
Yi Hu
Weidong Han

Frontiers in Oncology

doi 10.3389/fonc.2020.541330

7,253 views
38 citations

Systematic Review

Published on 23 Sep 2020

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis

in Thoracic Oncology

You-Meng Sun
Ying Wang
Xin-Xing Sun
Jing Chen
Zhi-Ping Gong
Hai-Yan Meng

Frontiers in Oncology

doi 10.3389/fonc.2020.558454

4,983 views
22 citations

1,976 articles

articles

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

The Resistance Mechanisms of Lung Cancer Immunotherapy

The Favorable Prognostic Factors for Superior Sulcus Tumor: A Systematic Review and Meta-Analysis

Evaluation of the Effect of Lymph Node Status on the Survival of Non-Small Cell Lung Cancer Patients With Brain Metastases: Applications of a Novel Grade Prognostic Assessment Score Model Involving N Stage

Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients

Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis

Thermal Ablation Versus Wedge Resection for Stage I Non-small Cell Lung Cancer Based on the Eighth Edition of the TNM Classification: A Population Study of the US SEER Database

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer

Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer

SABR-BRIDGE: Stereotactic ABlative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts During the COVID-19 Pandemic

Telemedicine in Oncology: Delivering on an Overdue Promise in the COVID-19 Era

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

Exosome-Derived LncRNAs in Lung Cancer

Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis